コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 baseline probing depth was 7.8+/-1.1 mm for bioabsorbable and 7.9+/-1.3 mm for nonresorbable barrier
3 ade calcium sulfate (CS) is a biocompatible, bioabsorbable, and clinically versatile ceramic for use
5 ion defects with a new polylactic-acid-based bioabsorbable barrier (test treatment) or a non-absorbab
6 atients were treated with a combination of a bioabsorbable barrier and coronally advanced flap techni
8 ares the outcomes obtained from the use of a bioabsorbable barrier device in combination with deminer
9 he effectiveness and the predictability of a bioabsorbable barrier in the treatment of human recessio
11 to evaluate the regenerative potential of 2 bioabsorbable barrier membranes without the use of graft
14 ustained release of 4% doxycycline through a bioabsorbable barrier would enhance the regenerative out
15 nt of DFDBA (GTR+DFDBA, or test group) and a bioabsorbable barrier, while the contralateral side rece
18 non-resorbable barriers and polylactic acid bioabsorbable barriers in humans with intrabony defects
19 88.2 +/- 9.6); the seven sites treated with bioabsorbable barriers resulted in 5.9 +/- 1.2 mm of CAL
21 and cementum regeneration following use of a bioabsorbable, calcium carbonate biomaterial in conjunct
26 o test the hypothesis that HA can serve as a bioabsorbable carrier for other substrates as well as it
28 n flap debridement (OFD), MBA, or MBA with a bioabsorbable collagen membrane (guided tissue regenerat
29 one of two possible treatment pairs, either bioabsorbable collagen membrane (Type I bovine tendon co
30 lone, bone graft [BG], and bone graft plus a bioabsorbable collagen membrane [BG + C]), anatomic fact
31 y compared the efficacy of a porcine-derived bioabsorbable collagen membrane and an expanded polytetr
32 ose of this study was to assess the use of a bioabsorbable collagen membrane as a barrier device in r
35 his newly introduced MBA, with and without a bioabsorbable collagen membrane, for the treatment of ma
38 of combined induced perio-endo lesions using bioabsorbable collagen membranes alone or in combination
40 hogenetic protein-2 (rhBMP-2) delivered on a bioabsorbable collagen sponge (ACS) compared to placebo
41 ollagen wound dressing material) or control (bioabsorbable collagen wound dressing material only) gro
42 randomly assigned to the test (Putty P15 and bioabsorbable collagen wound dressing material) or contr
43 -derived growth factor-BB (rhPDGF-BB) with a bioabsorbable collagen wound-healing dressing and a coro
44 reated with 0.3 mg/ml rhPDGF-BB + beta-TCP + bioabsorbable collagen wound-healing dressing; contralat
45 randomly selected for treatment with either bioabsorbable demineralized bone allograft membrane or e
46 ar furcation invasion defects using either a bioabsorbable demineralized laminar bone allograft membr
49 imus eluting stents (EES), thick-strut fully bioabsorbable EES, thick-strut biodegradable polymer met
53 e pipetted onto a 3-mm diameter x 2-mm thick bioabsorbable hemostatic gelatin and placed onto the sur
54 Here, we present a fully biodegradable and bioabsorbable high-performance supercapacitor implant, w
55 Our approach reveals that 3D printing of bioabsorbable implants containing anti-cancer drugs coul
57 surgical implantation of a space-providing, bioabsorbable, macroporous, polyglycolic acid-trimethyle
58 icity between the Magmaris sirolimus-eluting bioabsorbable magnesium scaffold and the Absorb bioresor
59 ut thickness, the Magmaris sirolimus-eluting bioabsorbable magnesium scaffold was significantly less
60 ak; however, if surgeons desire to buttress, bioabsorbable material is the most common type used.
62 There has been an increase in the use of bioabsorbable materials which do not require a second su
65 the same flap surgery followed by use of the bioabsorbable membrane alone (GTR, or control group).
66 Infrabony defects treated with GTR using a bioabsorbable membrane and a bone graft substitute with
68 es (10 patients) were treated with DFDBA and bioabsorbable membrane before placing endosseous implant
69 P), bovine porous bone mineral (BPBM), and a bioabsorbable membrane for guided tissue regeneration (G
72 ed freeze-dried bone allograft (DFDBA) and a bioabsorbable membrane is significantly less than the in
74 ts in 24 patients were treated with either a bioabsorbable membrane plus twice daily postsurgical nap
75 t of DFDBA in the furcation defect under the bioabsorbable membrane resulted in a greater mean reduct
80 polytetrafluoroethylene (ePTFE), GTR using a bioabsorbable membrane with or without demineralized fre
81 eatment of Class II furcation lesions with a bioabsorbable membrane with or without the adjunctive us
82 treatment of human gingival recession with a bioabsorbable membrane with or without the use of DFDBA
84 t with a bioabsorbable synthetic bone graft, bioabsorbable membrane, and minocycline root conditionin
85 ients were treated with either a polylactide bioabsorbable membrane, demineralized freeze-dried bone
86 en defect received a poly(lactic acid)-based bioabsorbable membrane, while the paired defect received
89 ylene [ePTFE] titanium reinforced membranes, bioabsorbable membranes alone, bioabsorbable membranes w
91 e are little data evaluating the efficacy of bioabsorbable membranes in the treatment of intrabony de
93 ed membranes, bioabsorbable membranes alone, bioabsorbable membranes with a bone replacement graft [c
94 t, second and fourth premolars, received the bioabsorbable membranes, made of glycolide and lactide p
98 udy was to evaluate the efficacy of nonwoven bioabsorbable nanofibrous membranes of poly(lactideco-gl
99 ibroblast growth factor (bFGF) was used in a bioabsorbable, non-hydroxyapatite, calcium phosphate cem
103 clinical effects of DFDBA associated with a bioabsorbable (polylactic acid) barrier membrane in the
104 techniques in intrabony defects utilizing a bioabsorbable, polylactic acid (PLA) barrier or the non-
105 estigate the relative safety and efficacy of bioabsorbable polymer (BP)-based biolimus-eluting stents
108 y of 2 dose formulations of SYNERGY, a novel bioabsorbable polymer everolimus-eluting stent (EES) (Bo
110 livery of everolimus by a unique directional bioabsorbable polymer system utilizing the SYNERGY stent
111 y and efficacy of durable polymer-based DES, bioabsorbable polymer-based biolimus-eluting stents (BES
114 and efficacy with MiStent sirolimus-eluting bioabsorbable polymer-coated stent are confirmed at a lo
115 flet heart valves were fabricated from novel bioabsorbable polymers and sequentially seeded with auto
116 y of fluoropolymer-coated CoCr-EES, DES with bioabsorbable polymers, and fully bioresorbable scaffold
119 : open flap debridement only (OFD), OFD with bioabsorbable porcine-derived collagen membrane (BG), or
121 ronary delivery of an innovative, injectable bioabsorbable scaffold (IK-5001), to prevent or reverse
123 pathomechanisms underlying restenosis of the bioabsorbable sirolimus-eluting metallic scaffold (Magma
127 enerative therapy by open debridement with a bioabsorbable synthetic bone graft, bioabsorbable membra
128 study was to assess the performance of a new bioabsorbable, synthetic polyglycolic acid/trimethylene
130 treated with either doxcycycline hyclate in bioabsorbable vehicle (DHV) or with vehicle control (VC)
131 The addition of doxycycline hyclate in a bioabsorbable vehicle used as a locally delivered drug d